Court Lifts Pfizer Seizure of Polish Aviation Funds in Brussels 2026

Belgium(Brussels Morning Newspaper)November  13,2026 – A court of first instance in Brussels has set aside a June 25 court order that froze over 80 per cent of the income belonging to the Polish Air Navigation Services Agency (PANSA). The initial asset seizure was executed in connection with an ongoing €1.3 billion ($1.4 billion) legal dispute initiated by pharmaceutical manufacturer Pfizer against the Polish government over COVID-19 vaccine payments. While the Belgian ruling restores PANSA’s access to its en-route aviation charges, both the agency and Polish authorities noted that the judgment is not final, and Pfizer confirmed it is pursuing alternative enforcement mechanisms.

A court of first instance in Brussels has officially overturned a legal order that had deprived Poland’s state air traffic control operator of fees accounting for more than 80 per cent of its total revenue. According to reporting by Reuters, the decision follows an objection lodged by the Polish Air Navigation Services Agency (PANSA) against the seizure of its operational funds. The freeze had been implemented as an enforcement measure linked to a high-value lawsuit brought by Pfizer against the Republic of Poland regarding unpaid bills for COVID-19 vaccines.

In an official statement released on Thursday, November 12, PANSA confirmed that it had received the formal ruling from the Brussels judicial authority. The Belgian court determined that the Polish agency’s objection to the asset freeze was “well-founded” and consequently set aside the previous court order dated June 25.

While the decision represents a procedural development in favour of the air traffic operator, PANSA explicitly noted in its Thursday statement that the judgment is not final and remains subject to potential further legal proceedings within the Belgian judicial system.

Legal Separation Between Polish State Treasury and Aviation Agency Assets

Following the announcement from Brussels, Poland’s Ministry of Health issued an official statement addressing the legal implications of the ruling for state liabilities. According to the ministry, the Belgian court confirmed that the revenue generated from “en-route charges”—the fees paid by airlines for air navigation services within Polish airspace—belongs directly to PANSA rather than to the Polish state treasury.

The Ministry of Health emphasised the distinct legal status of the air navigation agency in relation to the sovereign debt and contractual disputes of the central government. In its statement, the ministry declared that PANSA is not liable for the financial obligations of the state treasury, and therefore its designated operational funds cannot be seized or utilised to satisfy Pfizer’s financial claims against Poland.

En-route charges constitute the primary financial mechanism through which European air navigation service providers fund air traffic management, safety infrastructure, and operational personnel. The June 25 order had intercepted a substantial proportion of these incoming fees, impacting more than four-fifths of the agency’s regular income stream prior to Thursday’s reversal.

Pfizer Response and Ongoing €1.3 Billion Vaccine Contract Dispute

Pharmaceutical company Pfizer also issued comments on Thursday responding to the ruling by the Brussels court of first instance. In its statement, the company directed attention to an earlier substantive court ruling issued in April regarding the underlying contractual dispute with Warsaw.

Pfizer stated that the April ruling confirmed “the importance of the contractual obligations that underpinned Europe’s successful pandemic response.” Addressing the immediate impact of the November 12 decision in Brussels, the company clarified that Thursday’s ruling pertains exclusively to one specific avenue of enforcement regarding the April judgment, rather than altering the merits of the underlying payment claim.

“We are taking appropriate steps through established legal and contractual mechanisms to ensure compliance with the court’s decision,” Pfizer stated, referring to the enforcement of the April ruling against the Polish state.

Background of the Legal Proceedings Between Pfizer and Poland

The enforcement actions in Belgium stem from a broader, multi-year legal dispute initiated by Pfizer against Poland over approximately €1.3 billion (equivalent to $1.4 billion at an exchange rate of $1 to 0.9027 euros) in contested payments for COVID-19 vaccine doses.

Under European Union joint procurement agreements negotiated during the COVID-19 pandemic, member states committed to purchasing specified quantities of vaccines from manufacturers including Pfizer and its partner BioNTech. Disputes emerged after Poland declined to accept and pay for remaining shipments of vaccines, citing changing epidemiological conditions and financial pressures resulting from the war in neighbouring Ukraine and the hosting of refugees.

Pfizer subsequently initiated legal action in Brussels—the jurisdiction designated under the European Union’s vaccine supply contracts—seeking payment for the undelivered doses ordered under the agreement.

Chronology of Enforcement Measures in the Belgian Jurisdiction

The sequence of legal developments between the pharmaceutical manufacturer, the Polish government, and the Polish Air Navigation Services Agency encompasses several distinct judicial milestones in Belgium:

• April Court Ruling: A Belgian court issued a decision addressing the core contractual dispute brought by Pfizer against Poland over the €1.3 billion in vaccine payments, which Pfizer cited as confirming the validity of the pandemic-era supply obligations.

• June 25 Seizure Order: Following the April judgment, a court order was issued on June 25 enabling the seizure of funds linked to Poland, which resulted in the freezing of en-route aviation fees representing over 80 per cent of PANSA’s income.

• PANSA Legal Objection: The Polish Air Navigation Services Agency formally contested the June 25 seizure order before the Belgian courts, arguing that its revenue streams are legally separate from the Polish state treasury and cannot be attached to settle central government liabilities.

• November 12 Reversal: The court of first instance in Brussels ruled that PANSA’s objection was well-founded, setting aside the June 25 order while leaving the broader enforcement process and potential appeals open.

Operational Context of Air Navigation Funding in Europe

Within the European aviation framework, air navigation service providers such as PANSA collect en-route charges through centralised billing mechanisms coordinated at the European level, with funds subsequently remitted to national agencies to cover air traffic control operations. Because these cross-border financial flows pass through international clearing institutions in Brussels, creditors seeking to enforce judgments against sovereign states have frequently targeted funds transiting through Belgian entities.

Thursday’s ruling by the Brussels court of first instance establishes a judicial distinction between sovereign state assets and the dedicated operational revenues of Poland’s air navigation authority within the context of the June 25 enforcement order. Both PANSA and Poland’s Ministry of Health confirmed that the agency’s operational fees are legally insulated from the state treasury’s obligations, while Pfizer reiterated its intention to continue pursuing compliance with the April ruling through established legal channels.